July 25, 2018 / 6:37 AM / 3 months ago

BRIEF-Argenx: Publication Of Study Results From Phase 1 Of FcRn-Antagonist Efgartigimod

July 25 (Reuters) - ARGENX SE:

* ANNOUNCED ON TUESDAY PUBLICATION OF FULL STUDY RESULTS FROM PHASE 1 OF FCRN-ANTAGONIST EFGARTIGIMOD (ARGX-113) IN HEALTHY VOLUNTEERS

* PHASE 1 DATA SHOWS THAT THE FCRN ANTAGONIST EFGARTIGIMOD WAS OBSERVED TO HAVE FAVORABLE TOLERABILITY PROFILE AND LED TO SPECIFIC AND SUSTAINED REDUCTION OF TOTAL IMMUNOGLOBULIN G (IGG) LEVELS

* MULTIPLE DOSES OF EFGARTIGIMOD LOWERED IGG LEVELS ON AVERAGE BY ABOUT 75% WITH LEVELS RETURNING TO BASELINE APPROXIMATELY EIGHT WEEKS FOLLOWING LAST ADMINISTRATION

* EFGARTIGIMOD WAS OBSERVED TO BE SELECTIVE TO IGG AND DID NOT AFFECT THE HOMEOSTASIS OF ALBUMIN OR IMMUNOGLOBULINS OTHER THAN IGG

* ARGENX IS STUDYING EFGARTIGIMOD IN PHASE 2 PROOF-OF-CONCEPT TRIAL IN IMMUNE THROMBOCYTOPENIA EXPECTED TO READ OUT IN Q3 2018

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below